- Home
- OB vs ENGN Comparison
OB vs ENGN Comparison
Compare OB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OB
- ENGN
- Stock Information
- Founded
- OB 2006
- ENGN 1999
- Country
- OB United States
- ENGN Canada
- Employees
- OB N/A
- ENGN N/A
- Industry
- OB Industrial Machinery/Components
- ENGN
- Sector
- OB Industrials
- ENGN
- Exchange
- OB Nasdaq
- ENGN Nasdaq
- Market Cap
- OB 269.6M
- ENGN 317.6M
- IPO Year
- OB 2021
- ENGN N/A
- Fundamental
- Price
- OB $6.61
- ENGN $6.97
- Analyst Decision
- OB Buy
- ENGN Strong Buy
- Analyst Count
- OB 5
- ENGN 9
- Target Price
- OB $6.66
- ENGN $29.78
- AVG Volume (30 Days)
- OB 288.1K
- ENGN 108.9K
- Earning Date
- OB 02-27-2025
- ENGN 03-10-2025
- Dividend Yield
- OB N/A
- ENGN N/A
- EPS Growth
- OB N/A
- ENGN N/A
- EPS
- OB N/A
- ENGN N/A
- Revenue
- OB $903,518,000.00
- ENGN N/A
- Revenue This Year
- OB $0.80
- ENGN N/A
- Revenue Next Year
- OB $8.13
- ENGN N/A
- P/E Ratio
- OB N/A
- ENGN N/A
- Revenue Growth
- OB N/A
- ENGN N/A
- 52 Week Low
- OB $3.42
- ENGN $4.42
- 52 Week High
- OB $7.87
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- OB 50.89
- ENGN 46.21
- Support Level
- OB $6.36
- ENGN $6.32
- Resistance Level
- OB $6.53
- ENGN $8.40
- Average True Range (ATR)
- OB 0.27
- ENGN 1.03
- MACD
- OB -0.11
- ENGN 0.01
- Stochastic Oscillator
- OB 48.98
- ENGN 37.71
About OB Outbrain Inc.
Outbrain Inc is a platform powering the open web that matches audiences with personalized content and ads, driving quality engagement. Its platform delivers ads to end-users that appear as links to articles, products, and videos on media partners' sites. It derives revenue from advertisers through user engagement with the ads that it places on media partners' web pages and mobile applications. The company has its geographic presence in Europe, the Middle East, and Africa followed by the USA and others.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.